DDInter1008 DDInter1376
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ketoconazole {u} (Compound) resembles {v} (Compound) Itraconazole
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Ketoconazole {u} (Compound) binds {v} (Gene) CYP3A4
Ketoconazole {u} (Compound) upregulates {v} (Gene) FDFT1
Ketoconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A5 Inhibitors
Ketoconazole {u} (Compound) downregulates {v} (Gene) PPP2R3C
Ketoconazole {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Ketoconazole {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) CYP51A1
Ketoconazole (Compound) resembles Itraconazole (Compound)
Ketoconazole (Compound) resembles Posaconazole (Compound)
Ketoconazole (Compound) binds CYP3A4 (Gene)
Ketoconazole (Compound) upregulates FDFT1 (Gene)
Ketoconazole (Compound) is included by Cytochrome P450 3A5 Inhibitors (Pharmacologic Class)
Ketoconazole (Compound) downregulates PPP2R3C (Gene)
Ketoconazole (Compound) causes Hypersensitivity (Side Effect)
Ketoconazole (Compound) binds CYP51A1 (Gene) and Ketoconazole (Compound) upregulates CYP51A1 (Gene)